Progress of Bruton tyrosine kinase inhibitor combined regimens in treatment of diffuse large B-cell lymphoma

VernacularTitle:布鲁顿酪氨酸激酶抑制剂联合方案在弥漫大B细胞淋巴瘤治疗中的研究进展
Author: Wanwan ZHANG ¹ ; Chongchong REN ; Tingkai WU ; Bei LIU
Author Information

1. 兰州大学第一临床医学院，兰州　730030
Keywords: Lymphoma, large B-cell, diffuse; Protein kinase inhibitors; Antineoplastic combined chemotherapy protocols; Bruton tyrosine kinase
From: Journal of Leukemia & Lymphoma 2024;33(8):505-509
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma (DLBCL) can be caused by multiple factors, including virus and autoimmune function, which in turn trigger persistent activation of the B-cell receptor (BCR) signaling pathway and other related signaling pathways, which collectively promote malignant B-cell proliferation and lead to tumor formation. Studies have shown significant progress in the treatment of primary and relapsed/refractory DLBCL with Bruton tyrosine kinase inhibitor (BTKi) in combination with chemotherapy, immunotherapy and small molecule inhibitors in the setting of poor outcome with BTKi monotherapy. This article reviews the progress of BTKi combined regimens in DLBCL.